

LABOUR PRODUCTIVITY GROWTH IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES UNDERGOING BIOLOGICAL OR JANUS KINASE INHIBITORS TREATMENT

Mercadal Orfila G (1), Ventayol Bosch P (2), Gómez Zamora M (2), Maestre Fullana MA (3), Bello Crespo M,(3), Fernández Cortes F(4) Serrano Lopez de las Hazas JI (5), Herrera Pérez S(6)

1 Pharmacy Service, Hospital Mateu Orfila, Menorca-Illes Balears (Spain), 2 Pharmacy Service, Hospital Universitari Son Espases, Palma de Mallorca-Illes Balears (Spain), 3 Pharmacy Service, Hospital Manacor, Manacor (Spain), 4 Pharmacy Service, Hospital Inca, (Spain), 5 Pharmacy Service, Hospital Son Llätzer, Palma de Mallorca-Illes Balears (Spain), 6 Universidad Internacional Valencia.

Number 6ER-006 L04- IMMUNOSUPPRESSANTS

Contact data: gabriel.mercadal@hgmo.es

Background and importance:

Work disability, especially in immune-mediated inflammatory diseases (IMIDs), has significant socio-economic implications. Biological therapies and Janus kinase inhibitors (JAKi) are key treatments for IMIDs. Recognizing the treatment and disease effects on work is vital for informed decisions. Analyses comparing the safety, efficacy, and costs of these treatments guide healthcare professionals and policymakers.

Aim and objectives

This study assesses the labor impact of biologic therapies and JAKi in patients with rheumatic, dermatological, and gastrointestinal autoimmune diseases. The assessment will employ the **Work Role Functioning Questionnaire (WRFQ)**, designed to measure work disability and the perceived influence of health conditions on job performance.


Materials and methods:

A cohort of 138 patients diagnosed with IMIDs was selected from five Spanish public hospitals. The study spanned from April 2021 to August 2022, with a one-year follow-up after initiating or switching to biologic therapy or JAK inhibitors. Remote data collection (www.navetahealth.com) utilized the WRFQ, comprising 27 items in five subscales. Comparative analysis employed a paired t-test with STATA 17.0 software.

Results:

The study involved 138 IMIDs patients, with 53.4% being female and a mean age of 50.5 years (range: 18-90). Over a 12-month follow-up, clinical and statistically significant improvements in work performance were observed.

Work Role Functioning Questionnaire



Conclusion and relevance :

This study underscores a **significant improvement in work performance among patients utilizing biologic drugs or JAKi therapies**. This positive outcome serves to reinforce the value and cost-effectiveness of these treatments, thereby mitigating their substantial impact on healthcare budgets. The findings hold relevance for healthcare professionals and policymakers alike, guiding them toward more informed decisions regarding IMIDs management.

References

Amick BC 3rd, Lerner D, Rogers WH, Rooney T, Katz JN. A review of health-related work outcome measures and their uses, and recommended measures. Spine (Phila Pa 1976). 2000 Dec 15;25(24):3152-60. doi: 10.1097/00007632-200012150-00010. PMID: 11124731.

